Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(4 sites)
United States
Stanford Cancer Institute Palo Alto, Palo Alto, California OHSU Knight Cancer Institute, Portland, Oregon University of Utah, Salt Lake City, Utah Fred Hutchinson cancer research center, Seattle, Washington Last updated December 2025